Organization & Developments: Adaptive Phage

Parents

Adaptive Phage Therapeutics Inc.

Children

2019: Gaithersburg firm taking down superbugs just raised $7M. Here’s its plan._ bizjournals
2020: Adaptive Phage Therapeutics lands $10.2M DOD contract for war on superbugs
2020: Md. firm’s treatment gets key FDA nod for some Covid patients with drug-resistant infections
2021: Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research
2021: Adaptive Phage Therapeutics Awarded Additional $8 Million from U.S. Department of Defense for Clinical Advancement of Phage to Address Unmet Needs in Infectious Diseases – Adaptive Phage Therapeutics
2022: APT is the sponsor to ongoing clinical trials in Prosthetic Joint Infection (PJI) and Diabetic Foot Osteomyelitis (DFO), addressing notable unmet patient need in those bacterial infection indications.
2022: Gaithersburg’s Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial_Biohealth Innovation
Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.
APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage.
PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale.
Prior antimicrobial therapeutic approaches have been ”fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time.

Jumps

Finance & Acquisitions: Adaptive Phage
Key People: Adaptive Phage

Made with TheBrain